A phase II study of neoadjuvant chemotherapy followed by organ preservation in patients with muscle-invasive bladder cancer

[1]  Prashant Mathur,et al.  Cancer Statistics, 2020: Report From National Cancer Registry Programme, India , 2020, JCO global oncology.

[2]  R. Bristow,et al.  Neoadjuvant Chemotherapy Before Bladder‐Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle‐Invasive Bladder Cancer , 2019, Clinical genitourinary cancer.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  Wei-Ting Hwang,et al.  Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial , 2017, JAMA surgery.

[5]  T. H. van der Kwast,et al.  Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Niemierko,et al.  Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. , 2017, European urology.

[7]  J. Donovan,et al.  Clinical and patient‐reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy , 2017, BJU international.

[8]  L. Eapen,et al.  The Rationale for Post-Operative Radiation in Localized Bladder Cancer , 2017, Bladder cancer.

[9]  Y. Lotan,et al.  Bladder cancer , 2016, The Lancet.

[10]  M. Milowsky,et al.  Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  K. Gaston,et al.  Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer. , 2016, Urologic oncology.

[12]  O. Sager,et al.  Outcomes of Trimodality Approach in the Management of T2N0M0 Bladder Cancer , 2015, Tumori.

[13]  K. Hoffman,et al.  Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Ghoneim,et al.  Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation. , 2014, Clinical genitourinary cancer.

[15]  W. Meinhardt,et al.  Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone , 2014, BJU international.

[16]  C. Tangen,et al.  Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710 , 2014, Cancer.

[17]  R. Huddart,et al.  Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004) , 2013, International Journal of Radiation Oncology, Biology, Physics.

[18]  J. Jakubowicz,et al.  Transurethral resection, neoadjuvant chemotherapy and accelerated hyperfractionated radiotherapy (concomitant boost), with or without concurrent cisplatin, for patients with invasive bladder cancer – clinical outcome , 2013, Contemporary oncology.

[19]  N. Vogelzang,et al.  Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer. , 2013, The Journal of urology.

[20]  R. Wahlqvist,et al.  Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. , 2012, European urology.

[21]  R. Hautmann,et al.  Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. , 2012, European urology.

[22]  A. Niemierko,et al.  Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.

[23]  A. Roychoudhury,et al.  Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. , 2012, Urology.

[24]  T. Wilt,et al.  Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma , 2011, BJU international.

[25]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  L. Muren,et al.  CT-guided intensity-modulated radiotherapy for bladder cancer: isocentre shifts, margins and their impact on target dose. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Logue,et al.  Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[28]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[29]  R. Hautmann,et al.  Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. , 2005, The Journal of urology.

[30]  H. Grossman,et al.  Surgical factors influence bladder cancer outcomes: a cooperative group report. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Zietman,et al.  Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. , 2003, The Journal of urology.

[32]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[33]  H. Sandler,et al.  Overview of bladder cancer trials in the Radiation Therapy Oncology Group , 2003, Cancer.

[34]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Dunst,et al.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  B. Donnelly,et al.  Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of radiation therapy oncology group 89-03. , 1998, The Journal of urology.

[38]  S. Johansson,et al.  Long-term followup of a bladder carcinoma cohort: questionable value of radical radiotherapy. , 1997, The Journal of urology.

[39]  N. Geller,et al.  Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.

[40]  J. Logue,et al.  Radiation therapy for muscle-invasive bladder cancer: treatment planning and delivery in the 21st century. , 2005, Seminars in radiation oncology.